NCT01820858Active, not recruitingPhase 3
The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma
A Multicenter, Prospective, Randomized Trial of the Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma
Source: ClinicalTrials.gov · Last updated 2 Apr 2024
Brief summary (registry, in English)
This randomized trial is studying the efficacy and safety of the chemotherapy compared with radiation therapy alone as adjuvant treatment after operation in Patients with high risk and Stage I endometrial carcinoma.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 20 Mar 2013
- Start date
- Nov 2012
- Primary completion date
- Dec 2025
- Lead sponsor
- Ding Ma
- Diseases
- Endometrial cancer
- NCT number
- NCT01820858
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 300
- From Nov 2012 to the primary completion date, Dec 2025
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Unable to receive surgery and/or unsuitable for radiotherapy or chemotherapy;
Other illness
- Family history of ovarian cancer;
- Suffering from other malignancies;
Other
- Concurrently participating in other clinical trials;
- Unable or unwilling to sign informed consents;
- Unable or unwilling to abide by protocol.
Who the study is looking for
- FIGO stage: Ⅰ, endometrial carcinoma;
- Female, Chinese women;
- Initial treatment is staging surgery;
- Pathological diagnosis: Endometrial adenocarcinoma;
- Pathologic examination and meet the following one of the indications of adjuvant therapy: ① histopathological grading in poorly differentiated: G3; ② ≥50% myometrial invasion; ③ vascular space involvement;
- No prior treatment;
- Provide written informed consent.
Age in the registry: 18 years to 65 years · Sex: Female · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Women's hospital school of medicine Zhejiang University Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
| Qilu Hospital，Shandong University Coordinator of this site? Confirm its status | Jinan | China | Unknown status |
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.